Baopowder Poised to Dominate the Nutritional Supplement industry with its Single Serving Packs of Baobab Powder

A pack of Baopowder

Baopowder

Baobab fruit

Daring marketing

With companies struggling to be known and get their product out, Baopowder has found success in single serving packs and a daring marketing campaign

NEW YORK, NEW YORK, UNITED STATES, August 30, 2018 /EINPresswire.com/ —

For those of you that do not know, the tree that Rafiki drew Simba on in The Lion King is called The Baobab Tree. Known as the Tree of Life, it;s fruit, the baobab fruit is the most nutrient dense whole fruit on the planet. A fruit used for centuries by African tribes, for its medicinal and nutritional benefits is virtually unknown in the western world. The symbolism of Rafiki using an unripe Baobab fruit to rub on Simba's forehead as a cub is lost to many.

Still considered a "new" item, there are only a handful of companies that sell baobab fruit powder here in the west, and one of the biggest obstacles these companies face is educating the public about their product. Not so much for Baopowder. Instead, they decided to build a brand and aim for convenience, as they currently boast being the only company in the world that makes single serving packs. Which is super convenient, as opposed to other companies selling in bulk, and you would have to leave it at home. Add their most recent daring marketing campaign, and it seems they have found the formula others have not.

The baobab fruit is the only fruit in the world to dry naturally on the branch. It is Vegan, Gluten free, Organic, In Africa the baobab fruit is used to naturally address many ailments. Unlike most fruits it is low in sugar and calories, as well as being low in sodium. What it does possess in abundance is Vitamin C, prebiotics, calcium, fiber, potassium, zinc, Vitamin A, magnesium, thiamin, B6 and a number of different bioflavonoids. Of course, the health benefit of all of these things, and especially receiving them in an organic nature-based way, is well known and universally established. The most popular way to consume Baopowder is to mix it into smoothies, or adding it to warm or cool water. It is one of the few fruits whose nutritional value is not affected by heat, so that opens a wide variety of consumption methods. Smoothies, juice, water, coffee, tea, soup, pancake mix are among many foods you can add baobab powder to. It can also be sprinkled on pastries. A study conducted by Oxford Brookes University found that baobab fruit powder, baked into white bread, slowed the absorption of starchy food glycemic response in humans. This reduces spikes and crashes in blood sugar and energy. Researchers believe the fruit may block enzymes that break down starch and sugar, in addition to slowing absorption with its fiber content. It is reported to have antimicrobial, anti-inflammatory, antimalarial, antidiarrheal, antiviral, and antioxidant properties, and to be useful in treating or preventing anemia and asthma.

Though, more research is needed into these health claims, so far, some very reputable medical institutions have backed up the claims. And Big name publications like Forbes Magazine publishing articles about it with said claims only seem to legitimize it and back up these claims

Isa Bako. The COO at Baopowder said the response they have gotten from health stores and Natural food markets has been largely positive. While only in the market for 4 months, Baopowder has seen success in stores where competition's products have stalled.

For more information, be sure to check out www.baopowder.com.

Isa Bako
Baopowder
3477970379
email us here


Source: EIN Presswire

Small Water Enterprises: Providing Safe Drinking Water for Resilient Cities at Stockholm World Water Week

-Report authors, SWNI and NIUA are both partners of USAID Urban WASH Alliance
-Report released by Mrs. Anita Shukla, First Secretary, Indian Embassy, Sweden

Including SWEs in urban planning for the creation of resilient cities expand the options for the Government to develop PPPs and facilitate direct investments that will contribute to urban growth.”

— Ravindra Sewak, India Country Director, Safe Water Network

STOCKHOLM, SWEDEN, August 30, 2018 /EINPresswire.com/ — Delhi/ Stockholm, August 29, 2018: The report on Small Water Enterprises: Providing Safe Drinking Water for Resilient Cities, a collaboration between Safe Water Network India and the National Institute of Urban Affairs (NIUA), USAID Urban WASH Alliance Partners, puts forward recommendations to support the transformation of India’s cities from water stressed to resilient with respect to safe drinking water.

Small Water Enterprises can benefit not only growing cities of India but other cities in the world struggling to mitigate climate change and keep pace with rapid urbanization. Cities and their residents who are seeking a better future need 24×7 access to safe, affordable water in easy reach of their living and working spaces. The report recommends including Small Water Enterprises (SWEs) as decentralized safe drinking water solution in city planning for the creation of resilient cities and thereby achieving the twin benefits of safe water for citizens and livelihood generation. It highlights the benefits and potential of expanding the SWE category in the urban environment, and recommends enhanced collaboration and partnerships between the Government and the private sector to achieve this objective.

At the launch of the report, Ravindra Sewak, India Country Director, said “Nearly 820 million people in India live beyond treated piped water. Niti Aayog’s Composite Water Management Index (CWMI) Report highlights that India is facing the worst water crisis in its history, with millions of lives and livelihoods under threat today. The crisis is only going to get worse. By 2030, the country’s water demand is projected to be twice the available supply, implying severe water scarcity for hundreds of millions of people and an eventual ~6% loss in the country’s GDP.
Small Water Enterprises provide a safe, reliable, affordable and sustainable alternative to address the need gap in many towns and cities. SWEs can fill the gap and compliment Urban Local Bodies’ (ULBs) effort towards providing piped water supply. Including SWEs in urban planning for the creation of resilient cities expand the options for the Government to develop public private partnerships, facilitate direct investments and development in ways that will support, and contribute to urban growth and renewal.”

Prof Jagan Shah, Director, National Institute of Urban Affairs said, “Cities face a growing range of adversities and challenges. Resilience is what enables them to adapt and transform in the face of these challenges, helping them to prepare for both the expected and the unexpected. In April 2018, 100 Resilient Cities (100RC) pioneered by the Rockefeller Foundation and the National Institute of Urban Affairs (NIUA) announced a formal partnership to expand collaborative resilience-building efforts in India. Safe drinking water supply is prominent among the adversities and challenges facing India especially as migration and the pace of growth of urban cities and slums accelerates.”
He further added, “The current infrastructure broadly, and the provision of safe water supply specifically, are insufficient to meet the demands of the increasing population. The Government needs to create the most conducive enabling environment to facilitate opportunities for business to contribute to innovation, and for local community initiatives to thrive. Small water enterprises are one such initiative that can meaningfully contribute to safe water supply and resilient cities.”

Sri Bonthu Rammohan, Mayor of Hyderabad city, said, “The city of Hyderabad alone, needs 800 such 24×7 SWE solutions so that citizens do not need to buy expensive plastic bottled water. It also prevents the environmental pollution due to plastic bottles.” Under his leadership, the city has set up hundreds of small water enterprises already.

In India, nearly 17 percent of the urban population (65 million people) live in slums and more than 50 percent of the 14 million urban poor families lack access to safe piped water supply. This gap in supply is often met by Urban Local Bodies (ULBs) through provision of community-level standpipes or tankers. However, the quality of water from these sources is usually unsafe, and water supply is often available for only a few hours a day, thus leading to water conflicts at the collection point, water borne disease and also the loss of economic opportunity.

SWEs address this unmet need to provide high-quality treated water, complementary to the Government’s piped water efforts. To achieve this objective, SWEs are included in the SMART cities and AMRUT city program by the Ministry of Housing and Urban Affairs. However, there is need of increased funding and conducive policy and enabling environment and regulatory framework is needed for the advancement of SWEs and building safe drinking water security.

Poonam Sewak
Safe Water Network India
9810506490
email us here


Source: EIN Presswire

Franchise Business Review Releases Top 50 Franchises for Women

PORTSMOUTH, NEW HAMPSHIRE, UNITED STATES, August 30, 2018 /EINPresswire.com/ — The 50 Best Franchises for Women

Women are increasingly seeking opportunities for business ownership and the franchise model can provide the financial and personal freedom they’re looking for. While many women are a great fit for franchising, not all franchise opportunities are a good fit for women.

Women owned businesses generate over $1.6 trillion in revenue every year. And 43 percent of franchises have at least one female owner. Franchising is appealing in many ways – it can provide women with work-life balance and flexibility not typically attainable in the corporate world and offers the support and community that many women desire…if you find the right one.

Clearly, not all franchises are created equal. Franchise Business Review surveyed nearly 6,000 female franchisee across 300 franchise brands to identify the 50 brands with the most highly satisfied female franchisees. The brands on Franchise Business Review’s 2018 list of the Top Franchises for Women were all highly rated by the women who own them.

Click here to see the list of the Top Franchises for Women

Franchise Business Review is currently conducting research for the 2019 FBR50 Franchisee Satisfaction Awards, an annual ranking of the top franchises overall. If you are a franchisor, click here to find out how to qualify.

Sarah Brady
Franchise Business Review
603-373-1552
email us here


Source: EIN Presswire

Suicide Prevention and Social Determinants of Health Highlight Mental Health Integration Meetings

SALT LAKE CITY, UTAH, USA, August 30, 2018 /EINPresswire.com/ — New initiatives and new companies were on display at the Intermountain Healthcare’s 18th Annual Mental Health Integration (MHI) Retreat held at Intermountain Medical Center in Murray, Utah.

What matters to you? That is a central point that was asked throughout the MHI Retreat. The Retreat brought together providers in primary and specialty care, members of the psychiatry field, and community members for the purpose of addressing mental health and medical outcomes.

The theme illustrated talking about making connections for better mental health – not only with family and friends, but also doctor to patient.

Dr. Brenda Reiss-Brennan, Intermountain’s Behavioral Services clinical director, opened with talking the incredible lengths that providers have gone to so far to normalize mental health. Using mental health integration, Intermountain has pushed forward to treating the “whole person.”

Here are the highlights of the retreat:

• Intermountain’s new Zero Suicide Initiative, which focuses on getting upstream of situations and issues that lead to suicide. How to prevent suicide, get access to care, and seeking help for those in danger.

• The social determinants of health – non-medical social and economic challenges that can affect someone’s health.

• Shannon Phillips, MD, chief patient experience officer, and Anne Pendo, MD, internal medicine medical director, showed how the patient experience has changed. The need is to not think of the patient going to the doctor, but the doctor going to the patient – by finding their interests and values.

• Panel discussion of clinic programs, pediatrics, cardiovascular, pregnancy and newborn and psychiatry showed how mental health integration has helped their patients and the need to expand the service to more specialty care areas.

• Emerging technologies that benefit mental health including telehealth. Alluceo, an Intermountain Healthcare company that offers proven, team-based mental health integration services and technology, showcased their technology for screening patients for MHI. This included an app that can send information from patient to provider and then provider to patient for mental healthcare plans.

• Integrating primary care with chronic pain and how it addresses substance use. Staff from the Intermountain Layton Clinic presented about how an integrated referral process helps patients.

Intermountain Healthcare is a Utah-based not-for-profit system of 22 hospitals, 170 clinics, a Medical Group with about 2,300 employed physicians and advanced practice clinicians, a health plans group called SelectHealth, and other medical services. Intermountain is widely recognized as a leader in transforming healthcare through high quality and sustainable costs. For more information about Intermountain, visit www.intermountainhealthcare.org.

Daron Cowley
Intermountain Healthcare
801-442-2834
email us here


Source: EIN Presswire

SynDaver brings on new CFO as company prepares for projected 2020 IPO

SynDaver's newly appointed CFO, Terence Terenzi

SynDaver’s newly appointed CFO, Terence Terenzi

TAMPA, FLA., UNITED STATES , August 30, 2018 /EINPresswire.com/ — SynDaver, a medical technology manufacturing company focused on the creation of high-fidelity synthetic human and animal simulators for medical and veterinary training, announced on Tuesday that Terence Terenzi has joined the company as its new chief finance officer.

Terenzi comes with a wealth of experience in corporate finance, having spent the previous seventeen years serving both Coterie Restaurants Group LLC. and True Double TWO LLC., a Tampa-area property development company, in the capacity of president, CFO and co-owner. During this span, Terenzi split his time among various business affairs, including business planning, financial analysis, property acquisition and the design/operation of eight restaurant locations.

Additionally, from 2000 to 2009 Terenzi also served as CFO and co-owner of TWT Construction, which served national brand clients like Outback Steakhouse, Bonefish Grill, Starbucks and Tijuana Flats. Terenzi has extensive experience with publicly traded companies, including the IPO process and SEC offerings associated with Eckerd Drugs, Danka Business Systems and Checkers Drive-In restaurants.

“Terence is a great addition to our team and has a wide skillset that we will leverage as we move toward our Initial Public Offering,” said Dr. Christopher Sakezles, founder of SynDaver. “We’re seeing increasing worldwide acceptance of our products and are in the process of setting up operations in the UK, China, Brazil and India. Terence will be an invaluable asset throughout this process and as we continue to experience record growth.”

Prior to 2000, Terenzi worked for and served as president and CFO at Hops Grill and Microbrewery, helping grow its sales from $18M to $175M over a five-year span. He received his Bachelor of Science in accounting from the University of Florida and began his career at KMPG Peat Marwick in Tampa and served as an audit manager.

About SynDaver
Headquartered in Tampa, Florida, SynDaver is the world’s leading manufacturer of hyper-realistic, synthetic human and animal surgical trainers. SynDaver’s synthetic bodies simulate fully-functioning live organisms and are primarily used for training in schools, hospitals and military installations. SynDaver has the world’s largest database of live-tissue properties and all SynDaver tissues are made from water, salts and fibers. The company currently has 14 patents on these materials, processes and related products. Currently, SynDaver Labs employs more than 100 people at their facilities in the U.S. and is planning additional facilities in Europe, China, Brazil and India.

SynDaver products have been lauded by industry experts and earned a cult following after appearances on ABC’s Shark Tank, MythBusters, Grey’s Anatomy, and the series finale of CSI. The company's models are also expected to feature prominently in multiple episodes of the upcoming MythBusters 2.0.

James Judge
Judge Public Relations
813.279.8335
email us here


Source: EIN Presswire

Global Narcolepsy Market (Hospitals, Clinics, Retail Pharmacies) Size, Status and Forecast 2018 to 2025

Market Research Nest

Market Research Nest

MarketResearchNest.com adds “Global Narcolepsy Market Size, Status and Forecast 2018-2025” new reports to its research database.

PUNE, INDIA, August 30, 2018 /EINPresswire.com/ — MarketResearchNest.com adds “Global Narcolepsy Market Size, Status and Forecast 2018-2025” new reports to its research database. The report spread across 91 pages with tables and figures in it.

This report focuses on the global Narcolepsy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Narcolepsy development in United States, Europe and China.

Narcolepsy is a neurological disorder that affects the control of sleep and wakefulness. People with narcolepsy experience excessive daytime sleepiness and intermittent, uncontrollable episodes of falling asleep during the daytime. These sudden sleep attacks may occur during any type of activity at any time of the day.

Inquire before Buying at https://www.marketresearchnest.com/report/enquirybuy/419650 .

People with narcolepsy can be substantially helped, but not cured. Treatment is tailored to the individual, based on symptoms and therapeutic response. The time required to achieve optimal control of symptoms is highly variable and may take several months or longer. Medication adjustments are frequently necessary, and complete control of symptoms is seldom possible. While oral medications are the mainstay of formal narcolepsy treatment, lifestyle changes are also important.

In 2017, the global Narcolepsy market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2018-2025.

The key players covered in this study
Jazz Pharmaceuticals
Bioprojet
Arena Pharmaceuticals
Graymark Healthcare
Mylan
Teva Pharmaceutical Industries
Novartis
Shire
Shionogi
Ligand Pharmaceuticals

Market segment by Type, the product can be split into
Type 1 Narcolepsy
Type 2 Narcolepsy

Market segment by Application, split into
Hospitals
Clinics
Retail Pharmacies

Order a purchase report copy of at https://www.marketresearchnest.com/report/purchase/419650 .

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central and South America

The study objectives of this report are:
• To analyze global Narcolepsy status, future forecast, growth opportunity, key market and key players.
• To present the Narcolepsy development in United States, Europe and China.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Narcolepsy are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025
For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Get a Report Details at https://www.marketresearchnest.com/Global-Narcolepsy-Market-Size-Status-and-Forecast-2018-2025.html .

About Us:
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.

Contact Us
Mr. Jeet Jain
Sales Manager
sales@marketresearchnest.com
+1-240-284-8070 / +44-20-3290-4151

Mr Jeet
Market Research Nest
1-240-284-8070
email us here


Source: EIN Presswire

Global Nano Therapy Market Size, Status and Forecast 2018 to 2025 Research Report Available at MarketResearchNest.com

Market Research Nest

Market Research Nest

MarketResearchNest.com adds “Global Nano Therapy Market Size, Status and Forecast 2018-2025” new reports to its research database.

PUNE, INDIA, August 30, 2018 /EINPresswire.com/ — MarketResearchNest.com adds “Global Nano Therapy Market Size, Status and Forecast 2018-2025” new reports to its research database. The report spread across 97 pages with tables and figures in it.

This report focuses on the global Nano Therapy status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Nano Therapy development in United States, Europe and China.

Nanotherapy is a branch of nanomedicine that involves using nanoparticles to deliver a drug to a given target location in the body so as to treat the disease through a process known as targeting.

Inquire before Buying at https://www.marketresearchnest.com/report/enquirybuy/419648 .

Much of the research in nanotherapy has been largely directed towards cancer therapy. One of the biggest issues with conventional methods is that as the drug product is distributed throughout the body, both healthy and unhealthy (cancerous cells) are affected, which in turn affects the effectiveness of cancer treatment. It is for this very reason that most cancer patients tend to be hesitant when it comes to chemotherapy. However, nanotherapy, which is also referred to as targeted therapy, offers to deliver the molecules to the affected cells in order to help treat the disease without causing other negative effects to the healthy cells.

In 2017, the global Nano Therapy market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2018-2025.

The key players covered in this study
Nanoprobes
Nanospectra Biosciences
Parvus Therapeutics
Smith And Nephew
Selecta Biosciences
Sirnaomics
Tarveda Therapeutics
Sirnaomics

Market segment by Type, the product can be split into
Nanomaterial And Biological Device
Nano Electronic Biosensor
Molecular Nanotechnology
Implantable Cardioverter-Defibrillators

Market segment by Application, split into
Cardiovascular Disease
Cancer Therapy
Diabetes Treatment
Rheumatoid Arthritis

Order a purchase report copy of at https://www.marketresearchnest.com/report/purchase/419648 .

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central and South America

The study objectives of this report are:
• To analyze global Nano Therapy status, future forecast, growth opportunity, key market and key players.
• To present the Nano Therapy development in United States, Europe and China.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Nano Therapy are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025
For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Get a Report Details at https://www.marketresearchnest.com/Global-Nano-Therapy-Market-Size-Status-and-Forecast-2018-2025.html .

About Us:
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.

Contact Us
Mr. Jeet Jain
Sales Manager
sales@marketresearchnest.com
+1-240-284-8070 / +44-20-3290-4151

Mr Jeet
Market Research Nest
1-240-284-8070
email us here


Source: EIN Presswire

Global Neurosyphilis Market (Asymptomatic, Meningeal, Meningovascular, General Paresis, Tabes Dorsalis) Forecast to 2025

Market Research Nest

Market Research Nest

MarketResearchNest.com adds “Global Neurosyphilis Market Size, Status and Forecast 2018-2025” new reports to its research database.

PUNE, INDIA, August 30, 2018 /EINPresswire.com/ — MarketResearchNest.com adds “Global Neurosyphilis Market Size, Status and Forecast 2018-2025” new reports to its research database. The report spread across 91 pages with tables and figures in it.

This report focuses on the global Neurosyphilis status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Neurosyphilis development in United States, Europe and China.

Neurosyphilis is an infection of the brain or spinal cord caused by the spirochete Treponema pallidum. It usually occurs in people who have had chronic, untreated syphilis, usually about 10 to 20 years after first infection and develops in about 25%-40% of those who are not treated. The United States' Centers for Disease Control and Prevention (CDC) advises that neurosyphilis can occur at any stage of a syphilis infection.

Inquire before Buying at https://www.marketresearchnest.com/report/enquirybuy/419663 .

Neurosyphilis has four different forms: asymptomatic, meningovascular, tabes dorsalis, and general paresis. In rare instances, active neurosyphilis can mimic Alzheimer's disease. In addition to evaluation of any symptoms and signs, various blood tests can be done. Additional tests to look for problems with the nervous system may include Cerebral angiogram, Head CT scan, Lumbar puncture and MRI scan of the brain, brainstem, or spinal cord.
In 2017, the global Neurosyphilis market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2018-2025.

The key players covered in this study
Abbott
Bayer
Eli Lilly and Company
GlaxoSmithKline
Novartis
Pfizer
Sanofi

Market segment by Type, the product can be split into
Asymptomatic Neurosyphilis
Meningeal Neurosyphilis
Meningovascular Neurosyphilis
General Paresis
Tabes Dorsalis

Market segment by Application, split into
Hospital And Clinics
Medical Research Centers
Academic Institutes

Order a purchase report copy of at https://www.marketresearchnest.com/report/purchase/419663 .

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central and South America

The study objectives of this report are:
• To analyze global Neurosyphilis status, future forecast, growth opportunity, key market and key players.
• To present the Neurosyphilis development in United States, Europe and China.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Neurosyphilis are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025
For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Get a Report Details at https://www.marketresearchnest.com/Global-Neurosyphilis-Market-Size-Status-and-Forecast-2018-2025.html .

About Us:
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.

Contact Us
Mr. Jeet Jain
Sales Manager
sales@marketresearchnest.com
+1-240-284-8070 / +44-20-3290-4151

Mr Jeet
Market Research Nest
1-240-284-8070
email us here


Source: EIN Presswire

Global Nystagmus Market (Early-onset, Acquired) Size, Status and Forecast 2018 to 2025 Research Report

Market Research Nest

Market Research Nest

MarketResearchNest.com adds “Global Nystagmus Market Size, Status and Forecast 2018-2025” new reports to its research database.

PUNE, INDIA, August 30, 2018 /EINPresswire.com/ — MarketResearchNest.com adds “Global Nystagmus Market Size, Status and Forecast 2018-2025” new reports to its research database. The report spread across 91 pages with tables and figures in it.

This report focuses on the global Nystagmus status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Nystagmus development in United States, Europe and China.

Nystagmus is a condition of involuntary eye movement, acquired in infancy or later in life, that may result in reduced or limited vision. Due to the involuntary movement of the eye, it has been called "dancing eyes".

There are two key forms of nystagmus: pathological and physiological, with variations within each type. Nystagmus may be caused by congenital disorders, acquired or central nervous system disorders, toxicity, pharmaceutical drugs, alcohol, or rotational movement. Previously considered untreatable, in recent years several drugs have been identified for treatment of nystagmus. Nystagmus is also occasionally associated with vertigo.

Inquire before Buying at https://www.marketresearchnest.com/report/enquirybuy/419668 .

In 2017, the global Nystagmus market size was xx million US$ and it is expected to reach xx million US$ by the end of 2025, with a CAGR of xx% during 2018-2025.

The key players covered in this study
Bristol-Myers Squibb
Nusapure
Allergan
Pfizer
Valeant Pharmaceuticals
Bayer
Aerie Pharmaceuticals

Market segment by Type, the product can be split into
Early-onset nystagmus
Acquired nystagmus

Market segment by Application, split into
Hospitals and Clinics
Research Centers

Order a purchase report copy of at https://www.marketresearchnest.com/report/purchase/419668 .

Market segment by Regions/Countries, this report covers
United States
Europe
China
Japan
Southeast Asia
India
Central and South America

The study objectives of this report are:
• To analyze global Nystagmus status, future forecast, growth opportunity, key market and key players.
• To present the Nystagmus development in United States, Europe and China.
• To strategically profile the key players and comprehensively analyze their development plan and strategies.
• To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Nystagmus are as follows:
History Year: 2013-2017
Base Year: 2017
Estimated Year: 2018
Forecast Year 2018 to 2025
For the data information by region, company, type and application, 2017 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Get a Report Details at https://www.marketresearchnest.com/Global-Nystagmus-Market-Size-Status-and-Forecast-2018-2025.html .

About Us:
MarketResearchNest.com is the most comprehensive collection of market research products and services on the Web. We offer reports from almost all top publishers and update our collection on daily basis to provide you with instant online access to the world’s most complete and recent database of expert insights on global industries, organizations, products, and trends.

Contact Us
Mr. Jeet Jain
Sales Manager
sales@marketresearchnest.com
+1-240-284-8070 / +44-20-3290-4151

Mr Jeet
Market Research Nest
1-240-284-8070
email us here


Source: EIN Presswire

Opioid epidemic and Scrambler Therapy®

Scrambler Therapy® (ST) has been specifically developed for chronic neuropathic and oncologic pain resistant to any type of treatment including opioids.

ROME, ITALY, August 30, 2018 /EINPresswire.com/ — Opioid epidemic and Scrambler Therapy®

“The opioid epidemic is one of the most profound public health crises facing the United States and the current crisis of opioid overdose deaths requires innovative approaches. The FDA remains committed to addressing this national crisis on all fronts, with a focus on encouraging medical product innovation to prevent new cases of opioid abuse and addiction and to treat those addicted.”Source: Food and Drug Administration (FDA)

Scrambler Therapy® Technology
Scrambler Therapy® (ST) is a non-invasive electro-analgesia therapy based on a new generation of medical device that uses 5 artificial neurons. The active principle with ST is such that synthetic “non-pain” information is transmitted by C fibers surface receptors (International Patent). Therefore, the traditional electric stimulation of A-Beta fibers to produce paraesthesia and/or block the conduction of nerve fibers to produce an analgesic effect, i.e., via TENS/SCS machines, is abandoned.

The significance of the problem it will solve.
Scrambler Therapy® (ST) has been specifically developed for pain resistant to any type of treatment including opioids. Published clinical trials have enrolled patients non-responsive to other protocol treatments. This makes it a good fit to use in place of opioid-based therapies.
At the current state of our knowledge, ST treatment does not produce undesired effects.

The impact on the public health.
– highly effective in very severe neuropathic and oncological pain, non-responsive to opioids, non-responsive to invasive spinal cord stimulators or other forms of electro-analgesia.
– few treatments (on average a cycle of 10 applications), repeatable in the time if necessary without developing resistance
– non-invasive, no known side effects, also applicable in paediatrics.
– If used correctly according to the standard protocols (it is an operator-dependent treatment) during the application the pain is immediately suppressed. In most cases the analgesic effect after the cycle treatment lasts for a long period and/or indefinitely.

About Delta International Service & Logistics (DIS&L)
DIS&L is an agency created for the international development of Scrambler Therapy® Technology, and selecting of medical device distributors in all international area. DIS&L through its law firm is the only company authorized to sign international exclusive agreements, provide maintenance and distributor support for method usage training and other logistics needs.
More info: https://www.st-team.eu , https://www.scramblertherapy-us.com
Video: https://www.st-team.eu/video.htm

Contact U.S. DIS&L Division:
Richard J. Erickson, North America Operations
6419 Hirondel St, Houston, TX 77087,406-249-0424
deltaintl3@gmail.com

About Scrambler Therapy® Technology
Scrambler Therapy® scientific research and development technology have been developed in Italy by Professor Giuseppe Marineo, who is the sole owner of its intellectual property rights. The official "Scrambler Therapy"® scientific and clinical information website is at https://www.scramblertherapy.org/english.htm

Mariella Giorgieri
Delta International Service & Logistics
+39 3921603399
email us here


Source: EIN Presswire